Skip to main content
. 2020 Jul 3;12:5345–5351. doi: 10.2147/CMAR.S254955

Table 1.

Baseline Clinical Characteristics of Patients

Characteristics Value
Gender, n (%)
 Male 8(80.0)
 Mean±SD 58.7±7.85
 Female 2(20.0)
Age (years)
 Median 56
 Range 46–71
Weight
 ≥60kg 5(50.0)
 <60kg 5(50.0)
Etiology, n (%)
 HBV 3(30.0)
 Unknow 7(70.0)
ECOG, n (%)
 1 7(70.0)
 2 3(30.0)
Child–Pugh class, n (%)
 A 7(70.0)
 B 3(30.0)
Serum CA19-9, n (%)
 ≥27U/mL 6(60.0)
 <27U/mL 4(40.0)
Tumor size(cm), n (%)
 Mean±SD 6.84±4.41
 ≥5cm 7(70.0)
 <5cm 3(30.0)
Number of tumors, n (%)
 1–3 4(40.0)
 >3 6(60.0)
Macroscopic vascular invasion, n (%)
 Yes 3(30.0)
 No 7(70.0)
Metastatic sites, n (%)
 Regional lymph nodes 10(100.0)
 Distant lymph nodes 3(30.0)
 Lung 6(60.0)
 Bone 4(40.0)
Biliary drainage
 Yes 2(20.0)
 No 8(80.0)
Previous therapy, n (%)
 No 5(50.0)
 Chemotherapy 1(10.0)
 Radiotherapy 1(10.0)
 Resection and chemoradiotherapy 2(20.0)
 TACE 1(10.0)
Disease stage, n (%)
 IIIB 3(30.0)
 IV 7(70.0)

Abbreviations: HBV, hepatitis B virus; ECOG, Eastern Cooperative Oncology Group; CA19-9, carbohydrate antigen 19–9; TACE, transarterial chemoembolization.